City
Epaper

Study shows tumour DNA in blood can predict lung cancer outcome

By IANS | Updated: January 13, 2025 16:35 IST

New Delhi, Jan 13 A team of British scientists has found that a blood test used to detect ...

Open in App

New Delhi, Jan 13 A team of British scientists has found that a blood test used to detect circulating tumour DNA can predict the outcome of lung cancer.

Circulating tumour DNA (ctDNA) is fragments of DNA released into the blood by tumours. It’s known to be important for disease prognosis but can be difficult to measure precisely.

In the study, scientists from the Francis Crick Institute and University College London used a whole-genome sequencing platform called NeXT Personal, which can detect very small amounts -- 1 part per million -- of ctDNA.

They used the platform to test blood plasma samples from 171 people with early-stage lung cancer.

The finding published on Monday in the journal Nature Medicine showed that people with a low level of ctDNA before surgery were less likely to relapse and had improved overall survival rates than people with a high level of ctDNA.

The high sensitivity of the test meant that smaller amounts of ctDNA could be detected, which prevented people with a lower amount of ctDNA from being incorrectly labelled ctDNA negative.

“We’ve shown that the presence or absence of tumour DNA in the blood was strongly predictive of prognosis. ctDNA testing, especially using ultrasensitive platforms, could help clinicians make more informed decisions about treatment and give patients a more accurate idea of how their disease might progress,” said James Black, Postdoctoral Clinical Fellow at the Francis Crick Institute.

Current treatment for early-stage lung cancer includes removing the tumour by surgery and with chemotherapy or immunotherapy. The treatment course depends on the stage of the tumour, which aims to achieve the highest chance of cure.

Meanwhile, the team noted that the test will next be assessed on samples from patients who have undergone surgery with the earliest stages of lung cancer. This will help evaluate if the presence of ctDNA post-operatively in blood can be used to infer future risk of relapse.

This could allow doctors to offer additional therapy after surgery, increasing the chance of curing patients, the scientists said.

Disclaimer: This post has been auto-published from an agency feed without any modifications to the text and has not been reviewed by an editor

Open in App

Related Stories

Other SportsTanush Kotian leads charge with 4-83 as South Africa A conclude Day 1 for 299/9

EntertainmentKaran Johar strikes a pose with B-town newbies Suhana Khan, Shanaya Kapoor at Ananya Panday's lavish birthday bash

BusinessSigmaVizin Electronics Powering Dreams, Building India's Future

CricketRohit Sharma–KKR Trade Rumours Quashed by Mumbai Indians: ‘Mushkil Hi Nahi, Namumkin Hai!’

TechnologyGovt promises strict action against counterfeit seeds and pesticides

Health Realted Stories

HealthRising infections from lesser-known bacterium, says PGI Chandigarh

HealthKerala: Medical college doctors threaten indefinite strike over govt apathy

Health129 more test positive for dengue in Manipur, case tally rises to 3,594 this year

HealthNiva Bupa delays cashless medical claim amid tussle with hospital

HealthCipla global CEO Umang Vohra to step down, Achin Gupta announces as successor